uniQure Inc.: uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)

~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical trials to reduce the rate of annual bleeds, reduce or eliminate the need for prophylactic

Related Keywords

United States ,Michigan ,Amsterdam ,Noord Holland ,Netherlands ,American ,Dennis Riedl ,Chiara Russo ,Ricardo Dolmetsch ,Mariae Cantor ,Tom Malone ,European Commission ,Drug Administration ,Laurencea Boxer Research Professor Of Pediatrics ,University Of Michigan ,American Society Of Hematology ,European Union ,European Association For Haemophilia ,Behring Pharmacovigilance Department ,European Economic Area ,New England Journal ,Annualized Bleeding Rate ,Steven Pipe ,Research Professor ,Annual Bleeding Rate ,American Society ,European Association ,Allied Disorders ,Safety Information ,Pharmacovigilance Department ,Qure Forward Looking ,License Agreement ,Annual Report ,Qure Contacts ,Uniqure ,Nnounces ,Pope ,Linical ,Trial ,Data ,Published ,England ,Journal ,Medicine ,Emonstrating ,Durability ,Mother ,Benefits ,Hemgenix ,Tranacogene ,Ezaparvovec ,Nrlb ,